These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18041893)

  • 21. Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics.
    Turturro F; Leary C; Stephens J; Veillon D; Lowery-Nordberg M
    J Clin Oncol; 2010 Aug; 28(22):e380-1. PubMed ID: 20458054
    [No Abstract]   [Full Text] [Related]  

  • 22. Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine.
    Lai SW; Huang TC; Ye RH; Wu YY
    Eur J Haematol; 2015 Mar; 94(3):273-6. PubMed ID: 24797511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypomethylating therapy and autoimmunity in MDS: an enigmatic relationship.
    Kotsianidis I; Spanoudakis E; Nakou E; Miltiades P; Margaritis D; Tsatalas C; Tzouvelekis A; Oikonomou A
    Leuk Res; 2012 Apr; 36(4):e90-2. PubMed ID: 22230300
    [No Abstract]   [Full Text] [Related]  

  • 24. Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment.
    Feldmann G; Brossart P; von Lilienfeld-Toal M
    Ann Hematol; 2013 Nov; 92(11):1577-9. PubMed ID: 23584506
    [No Abstract]   [Full Text] [Related]  

  • 25. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azacitidine-induced cryptogenic organizing pneumonia: a case report and review of the literature.
    Alnimer Y; Salah S; Abuqayas B; Alrabi K
    J Med Case Rep; 2016 Jan; 10():15. PubMed ID: 26791087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe phototoxic reaction secondary to subcutaneous 5-azacitidine.
    Keating M; Dasanu CA
    J Oncol Pharm Pract; 2017 Sep; 23(6):473-475. PubMed ID: 27450683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histiocytoid Sweet's syndrome potentially related to decitabine in a patient with myelodysplastic syndrome.
    Park JY; Park JS; Kim YC
    Eur J Dermatol; 2012; 22(6):811-2. PubMed ID: 23178879
    [No Abstract]   [Full Text] [Related]  

  • 29. Interstitial pneumonitis--An important differential diagnosis for pulmonary sepsis in haematology patients.
    Pillai AR; Sadik W; Jones PA; Thachil J
    Leuk Res; 2012 Jan; 36(1):e39-40. PubMed ID: 21996561
    [No Abstract]   [Full Text] [Related]  

  • 30. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
    Martin MG; Walgren RA; Procknow E; Uy GL; Stockerl-Goldstein K; Cashen AF; Westervelt P; Abboud CN; Kreisel F; Augustin K; Dipersio JF; Vij R
    Am J Hematol; 2009 Sep; 84(9):560-4. PubMed ID: 19650118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes].
    Garzás-Martín de Almagro MC; Gago Sánchez AI; Cuevas Asencio I; Reyes Malia M
    Farm Hosp; 2010; 34(4):204-8. PubMed ID: 20185350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Case of acute respiratory failure caused by drug-induced lung injury by shiniseihaito].
    Nakajima H; Sawaguchi H; Tsuji F; Miyamoto T; Nakajima S; Tohda Y
    Arerugi; 2008 Jan; 57(1):59-63. PubMed ID: 18239447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.
    Voso MT; Fianchi L; Criscuolo M; Greco M; D'Alo F; Hohaus S; Pagano L; Leone G
    Leuk Res; 2012 Jan; 36(1):e15-7. PubMed ID: 21907408
    [No Abstract]   [Full Text] [Related]  

  • 34. Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome.
    Iltar U; Alhan FN; Vural E; Ataş Ü; Sözel H; Doğan Ö; Boduroğlu A; Yücel OK; Salim O; Ündar L
    J Oncol Pharm Pract; 2022 Mar; 28(2):500-503. PubMed ID: 34636655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome.
    Tseng E; Alhusayen R; Sade S; Buckstein R; Prica A
    Br J Haematol; 2015 May; 169(4):461. PubMed ID: 25765235
    [No Abstract]   [Full Text] [Related]  

  • 36. Severe allergic reaction to hydrochlorothiazide mimicking septic shock.
    Mineo MC; Cheng EY
    Pharmacotherapy; 2009 Mar; 29(3):357-61. PubMed ID: 19249954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Case of Myelodysplastic Syndrome with Intestinal Behçet's Disease-Like Symptoms Treated by Prednisolone and Azacitidine.
    Endo M; Sekikawa A; Tsumura T; Maruo T; Osaki Y
    Am J Case Rep; 2015 Nov; 16():827-31. PubMed ID: 26590106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful therapy with high-dose steroids and cyclosporine for the treatment of carmustine-mediated lung injury.
    Zappasodi P; Vitulo P; Volpini E; Castagnola C; Nascimbene C; Corso A
    Ann Hematol; 2002 Jun; 81(6):347-9. PubMed ID: 12107568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azacitine (vidaza) for myelodysplastic syndrome.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient.
    Ichikawa K; Aritaka N; Ogura K; Komatsu N; Hirano T
    Geriatr Gerontol Int; 2014 Oct; 14(4):1006-7. PubMed ID: 25327907
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.